Mannatech Reports $15.2M Net Loss, Negative Equity, and Going Concern Warning in Delayed 10-K
Summary
Mannatech's 2025 10-K reveals a critical financial state with a $15.2 million net loss, negative shareholders' equity, and a going concern warning, compounded by declining sales, negative cash flow, and reliance on high-interest related-party debt.
Key Events
-
Going Concern Warning Issued
The independent auditor's report and management's discussion explicitly state substantial doubt about the company's ability to continue as a going concern for the next twelve months.
-
Significant Net Loss and Negative Equity
The company reported a net loss of $15.2 million for 2025, a sharp decline from a $2.5 million net income in 2024. Total shareholders' equity turned negative, from $8.6 million to a deficit of $5.2 million.
-
Declining Sales and Customer Base
Consolidated net sales decreased by 8.3% to $108.0 million in 2025, and the number of active associates and preferred customers declined by 14.3% to 114,000.
-
Negative Cash Flow from Operations
Cash flow from operating activities shifted from a positive $2.3 million in 2024 to a negative $3.0 million in 2025.
Analysis
Mannatech's delayed 10-K filing reveals a dire financial situation, with a substantial net loss of $15.2 million for 2025, a significant reversal from a $2.5 million net income in 2024. The company's shareholders' equity has turned negative, from $8.6 million to a deficit of $5.2 million, indicating severe financial distress. The auditor's report explicitly raises substantial doubt about Mannatech's ability to continue as a going concern, a critical red flag for investors. Operations also deteriorated, with a shift from a $1.4 million operating income in 2024 to a $0.4 million operating loss in 2025, alongside an 8.3% decline in net sales and a 14.3% drop in active associates and preferred customers. The company incurred $11.5 million in non-cash income tax charges, including a $9.7 million deferred tax liability on unremitted foreign earnings, further impacting the net loss. Cash flow from operations turned negative, using $3.0 million in 2025 compared to providing $2.3 million in 2024. The company also disclosed that ERP system issues led to an estimated loss of over $6.0 million in revenue. Subsequent to year-end, the company extended $3.6 million in unsecured notes payable to three directors, bearing a high 16% interest rate, highlighting its reliance on related-party financing amidst liquidity challenges. The CFO's employment agreement will not be renewed, and directors have elected to receive compensation in stock instead of cash, signaling further cost-cutting measures and financial strain.
At the time of this filing, MTEX was trading at $4.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $4.67 to $12.45. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.